Bionano Announces Three Publications Demonstrating OGM’s Utility for Cell and Gene Therapy
May 21, 2024 08:00 ET | Bionano Genomics
Optical genome mapping was used in three publications to successfully assess genome integrity in stem cells, CAR-T cells, and iPSCs.
Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 16:05 ET | Longeveron
Longeveron announces 2024 Q1 financial results and business update. Phase 2b study in rare pediatric disease HLHS on track to complete enrollment in 2024.
Longeveron Logo.jpg
Longeveron Announces Board of Directors Planned Transitions
May 10, 2024 16:05 ET | Longeveron
Longeveron announces planned transitions on its Board of Directors.
Therini Bio Logo.jpg
Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegenerative Ocular Diseases
May 08, 2024 09:00 ET | Therini Bio, Inc.
THN391, a mAb designed to block neuroinflammation triggered by fibrin, demonstrated effectiveness in protecting against vascular and neuronal degeneration
Longeveron Logo.jpg
Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
May 02, 2024 08:03 ET | Longeveron
Longeveron to report Q1 2024 financial results on May 14, 2024.
ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease
April 29, 2024 07:57 ET | ZyVersa Therapeutics
NLRP1 & pyrin govern inflammation in Alzheimer’s Disease, and release of inflammasome laden extracellular vesicles induces cardiovascular inflammation.
Longeveron Logo.jpg
Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering
April 18, 2024 16:05 ET | Longeveron
Longeveron raises $11.4 million in gross proceeds from warrent exercise offering and public offering.
Longeveron Logo.jpg
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
April 15, 2024 08:30 ET | Longeveron
Data from Longeveron's CLEAR MIND Phase 2a clinical trial evaluating Lomecel-B in Alzheimer’s Disease has been accepted for two presentations at AAIC.
Longeveron Logo.jpg
Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals
April 08, 2024 08:30 ET | Longeveron
CEO Letter to Shareholders. Update on overall strategy, business objectives, approach to capital allocation, and 2024 key priorities and goals.
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024
March 14, 2024 07:57 ET | ZyVersa Therapeutics
Mr. Glover will talk about inflammasomes, and how they trigger development and spread of damaging inflammation, the culprit behind many deadly diseases.